The biopharmaceutical startup is developing treatments for cancer and infectious diseases.

US-based biotechnology company PMV Pharmaceuticals, announced the appointment of Steven Holtzman, pharmaceutical company Biogen Idec’s executive vice president for corporate development, to its board of directors.

PMV Pharmaceuticals aims to harvest the biology of p53 and p53 pathway modulators for the treatment of cancer and other infectious human diseases. Based in California and Pennsylvania, the startup has received funding from venture capital firm InterWest Partners.

Holtzman said: “PMV Pharmaceuticals has assembled a world-class team. Now is the time to apply…